SCHEMBL3673078

SCHEMBL3673078

CC(C(=O)O)c1ccc2ccccc2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.55
ALDH1A1 P00352 3/20 0.55
PRNP P04156 3/20 0.55
RXFP1 Q9HBX9 3/20 0.55
NPSR1 Q6W5P4 2/20 0.55
MAPK10 P53779 1/20 0.55
MGAM O43451 1/20 0.50
CYP1A2 P05177 3/20 0.49
CNR2 P34972 1/20 0.46
KMT2A Q03164 1/20 0.46
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.42
RAB9A P51151 2/20 0.42
MAPT P10636 2/20 0.42
HTT P42858 2/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29457163 0.84 CYP1A2 (0.47) KDM4EALDH1A1PRNPRXFP1NPSR1
SCHEMBL27742507 0.83 ALDH1A1 (0.41) KDM4EALDH1A1PRNPRXFP1NPSR1
SCHEMBL7136011 0.82 ALDH1A1 (0.49) KDM4EALDH1A1PRNPRXFP1NPSR1
SCHEMBL30838558 0.80 ALDH1A1 (0.51) KDM4EALDH1A1PRNPRXFP1NPSR1
SCHEMBL7774729 0.80 MGAM (0.52) KDM4EALDH1A1PRNPRXFP1NPSR1
SCHEMBL27325063 0.79 MGAM (0.50) KDM4EALDH1A1PRNPRXFP1NPSR1
SCHEMBL27721065 0.79 MGAM (0.50) KDM4EALDH1A1PRNPRXFP1NPSR1
SCHEMBL1613317 0.79 MGAM (0.50) KDM4EALDH1A1PRNPRXFP1NPSR1
SCHEMBL27519044 0.79 KDM4E (0.51) KDM4EALDH1A1PRNPRXFP1NPSR1
SCHEMBL2310345 0.78 ALDH1A1 (0.48) KDM4EALDH1A1PRNPRXFP1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113248421-B Preparation method of nifedipine 合肥立方制药股份有限公司 2022-03-08 CN claimed
CN-113248421-A Preparation method of nifedipine 合肥立方制药股份有限公司 2021-08-13 CN claimed
CN-111253304-A Preparation method of nifedipine 合肥立方制药股份有限公司 2020-06-09 CN claimed
US-20230107256-A1 QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-04-06 US disclosed
CN-111517902-B Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof 清华大学 2022-06-14 CN disclosed
CN-113234009-B Preparation method of nifedipine 合肥立方制药股份有限公司 2022-03-08 CN disclosed
CN-113248421-B Preparation method of nifedipine 合肥立方制药股份有限公司 2022-03-08 CN disclosed
CN-113248421-A Preparation method of nifedipine 合肥立方制药股份有限公司 2021-08-13 CN disclosed
CN-113234009-A Preparation method of nifedipine 合肥立方制药股份有限公司 2021-08-10 CN disclosed
CN-111253304-B Preparation method of nifedipine 合肥立方制药股份有限公司 2021-07-06 CN disclosed
WO-2020155595-A1 AEROBIC OXIDATION SYSTEM CONTAINING SULFINIC ACID, SULFONIC ACID OR DERIVATIVES THEREOF AND PHOTOCATALYTIC OXIDATION METHOD THEREFOR 清华大学 2020-08-06 WO disclosed
CN-111253304-A Preparation method of nifedipine 合肥立方制药股份有限公司 2020-06-09 CN disclosed
US-20200102274-A1 QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2020-04-02 US disclosed
EP-3600317-A1 QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF The Board of Regents of The University of Texas System (US) 2020-02-05 EP disclosed
WO-2018183668-A1 QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-10-04 WO disclosed
US-7812038-B2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS, INC. (US) 2010-10-12 US disclosed
US-20060276476-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors BIEDIGER RONALD J 2006-12-07 US disclosed
US-6972296-B2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC. (US) 2005-12-06 US disclosed
EP-1196436-A2 PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE Bristol-Myers Squibb Pharma Company (US) 2002-04-17 EP disclosed
WO-2001002424-A2 PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE DU PONT PHARMACEUTICALS COMPANY (US) 2001-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276476-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors VCAM1, ICAM1, ITGA1 KDM4E 2631/4885ALDH1A1 53/4885PRNP 2530/4885
US-20200102274-A1 QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF NNMT, NAMPT, NNT KDM4E 1338/4885ALDH1A1 459/4885PRNP 3471/4885
US-20230107256-A1 QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF NNMT, NAMPT, NNT KDM4E 1248/4885ALDH1A1 755/4885PRNP 3146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.